Scarica l'app Stockscreener
780.19
0.56%
-4.42
Dopo l'orario di chiusura:
780.09
-0.10
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$784.61
Aprire:
$784.7
Volume 24 ore:
618.33K
Relative Volume:
0.58
Capitalizzazione di mercato:
$80.58B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
18.68
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
+3.21%
1M Prestazione:
+19.21%
6M Prestazione:
+31.82%
1 anno Prestazione:
+3.35%
Intervallo 1D:
$779.50
$788.98
Intervallo di 1 settimana:
$756.64
$790.98
Portata 52W:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Claims Biocon Drug Mimics Its Patented Medicine - Law360
Te Ahumairangi Investment Management Ltd Acquires 4,278 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Russell Investments Group Ltd. Has $91.14 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? - Barchart.com
Magnetar Financial LLC Has $247,000 Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Codex Capital Asset Management L.L.C. Trims Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients - Yahoo Finance UK
Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider - GlobeNewswire Inc.
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Is Regeneron’s Stock Price Surge Justified After Recent FDA Approvals? - simplywall.st
Rhenman & Partners Asset Management AB Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Hsbc Global Res to Strong-Buy Rating - MarketBeat
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 - Seeking Alpha
North Star Asset Management Inc. Buys Shares of 737 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Elo Mutual Pension Insurance Co Has $5.73 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Stock Jumped 60%? - Trefis
XTX Topco Ltd Acquires 11,667 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oak Associates Ltd. OH Has $4.30 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prudential Financial Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Evoq launches FDA-registered dark adaptation testing device for IRDs - Eyes On Eyecare
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Truist Financial - MarketBeat
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $770.00 at Scotiabank - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Buy Rating from Analysts at HSBC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Rhumbline Advisers Sells 2,508 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cetera Investment Advisers - MarketBeat
DCF Advisers LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Charles Schwab Investment Management Inc. Has $378.14 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
EU approves Sanofi and Regeneron’s Dupixent as first targeted therapy for chronic spontaneous urticaria - Seeking Alpha
Inside Regeneron’s 3-Million-Sample Bet On Collaborative Genomics - Citeline News & Insights
Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria - MarketScreener
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria - The Manila Times
Regeneron and Sanofi Announce European Commission Approval of Dupixent for Moderate-to-Severe Chronic Spontaneous Urticaria - Quiver Quantitative
Regeneron (NASDAQ: REGN) gets EU OK for Dupixent as first CSU therapy in over a decade - Stock Titan
FDA approves new EYLEA HD indication, expanded dosing intervals - Eyes On Eyecare
Truist Securities Lowers Price Target for Regeneron Pharmaceuticals (REGN) to $798 | REGN Stock News - GuruFocus
HSBC Initiates Buy Rating on Regeneron (REGN) with $890 Target - GuruFocus
Regeneron, Bayer Lose Eye Med Biosimilar Battle - Law360
Regeneron a new buy at HSBC on Eylea HD uptake, cancer therapy catalysts (REGN:NASDAQ) - Seeking Alpha
Scotiabank Raises Price Target for Regeneron Pharmaceuticals (RE - GuruFocus
1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month - Finviz
Mufg Securities Americas Inc. Has $1.21 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Truist Securities assumes coverage on Regeneron stock with Buy rating - Investing.com
HSBC Initiates Coverage on Regeneron Pharmaceuticals (REGN) with a 'Buy' Rating | REGN Stock News - GuruFocus
HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target - MarketScreener
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ensign Peak Advisors Inc - MarketBeat
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today - Sahm
Jim Cramer Says He "Should Have Been Recommending Regeneron" - Finviz
Jim Cramer Says He “Should Have Been Recommending Regeneron” - Insider Monkey
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.37%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):